-
公开(公告)号：US20230220090A1
公开(公告)日：2023-07-13
申请号：US18148807
申请日：2022-12-30
发明人： Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
IPC分类号： C07K16/28 , A61K39/00 , C07K16/24 , C12N5/0783
CPC分类号： C07K16/2866 , A61K39/001119 , C07K16/244 , C12N5/0636 , C07K2317/622 , C07K2319/33 , A61K2039/505 , A61K2039/5156 , C07K2317/76 , C07K2317/73 , C07K2319/03 , A61K2039/507 , C07K2317/24
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
-
12.发明申请公开(公告)号：US20230052970A1
公开(公告)日：2023-02-16
申请号：US17937488
申请日：2022-10-03
发明人： Jennifer Brogdon , Hilmar Erhard Ebersbach , David Glass , Thomas Huber , Julia Jascur , Carl H. June , Jihyun Lee , Joan Mannick , Michael C. Milone , Leon Murphy , Avery D. Posey , Huijuan Song , Yongqiang Wang , Lai Wei , Qilong Wu , Qiumei Yang , Jiquan Zhang
IPC分类号： C07K16/28 , A61K35/17 , C07K16/30 , C07K14/705 , A61P35/02 , A61P35/00 , A61K48/00 , C07K14/725 , C12N15/86
摘要： The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
-
公开(公告)号：US20220064316A1
公开(公告)日：2022-03-03
申请号：US17359211
申请日：2021-06-25
发明人： Jennifer Brogdon , Eugene Choi , Hilmar Erhard Ebersbach , David Jonathan Glass , Heather Huet , Carl H. June , Joan Mannick , Michael C. Milone , Leon Murphy , Gabriela Plesa , Celeste Richardson , Marco Ruella , Reshma Singh , Yongqiang Wang , Qilong Wu
IPC分类号： C07K16/28 , C07K14/725 , C07K19/00 , A61P35/00 , C07H21/04 , C07K14/715 , A61K39/395 , A61K38/17 , C12N5/00 , C12N15/63 , C07K14/705 , A61K35/12
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
-
公开(公告)号：US20210284752A1
公开(公告)日：2021-09-16
申请号：US17132674
申请日：2020-12-23
发明人： Jennifer Brogdon , Carl H. June , Andreas Loew , Marcela Maus , John Scholler
IPC分类号： C07K16/30 , C07K14/725 , C07K14/705 , C07K16/28 , C12N5/0783
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
-
15.发明授权公开(公告)号：US11026976B2
公开(公告)日：2021-06-08
申请号：US16664223
申请日：2019-10-25
发明人： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Walter Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
公开(公告)号：US20190263914A1
公开(公告)日：2019-08-29
申请号：US16210480
申请日：2018-12-05
发明人： Jennifer Brogdon , Boris Engels , David Jonathan Glass , Brian Granda , John Hastewell , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , William Raj Sellers , Huijuan Song , Brian Edward Vash , Jan Weiler , Qilong Wu , Li Zhou
IPC分类号： C07K16/28 , A61K31/436 , C07K14/725 , C07K14/705 , C07K14/74 , C12N9/90 , A61K35/17 , C07K14/71 , C12N9/12
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
-
公开(公告)号：US10253086B2
公开(公告)日：2019-04-09
申请号：US15094674
申请日：2016-04-08
发明人： Hans Bitter , Jennifer Mary Bordeaux , Barbara Brannetti , Jennifer Brogdon , Naveen Kumar Dakappagari , Saar Gill , Steven Highfill , Lu Huang , Carl H. June , Ju Young Kim , Ming Lei , Na Li , Andreas Loew , Elena Orlando , Marco Ruella , Thai Tran , Jimin Zhang , Li Zhou
IPC分类号： A61K38/00 , A61K39/00 , A61K45/06 , C07K16/28 , C07K14/705 , C07K14/725
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
18.发明申请公开(公告)号：US20170183415A1
公开(公告)日：2017-06-29
申请号：US15400096
申请日：2017-01-06
发明人： Jennifer Brogdon , Saar Gill , Carl H. June , Michael D. Kalos , Andreas Loew , John Scholler
IPC分类号： C07K16/28 , A61K35/17 , A61K38/17 , C07K14/705 , A61K39/395 , A61K35/28 , C07K14/725
CPC分类号： C07K16/2866 , A61K35/17 , A61K35/28 , A61K38/1774 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61K2039/5158 , C07K14/7051 , C07K14/70517 , C07K16/2803 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/30 , C07K2319/33
摘要： The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
-
公开(公告)号：US20240252538A1
公开(公告)日：2024-08-01
申请号：US18529915
申请日：2023-12-05
发明人： Barbara Brannetti , Jennifer Brogdon , Boris Engels , Brian Walter Granda , Lu Huang , Ming Lei , Na Li , Jimin Zhang , Carla Patricia Pinto Guimaraes , Saar Gill , Marco Ruella , Regina M. Young
CPC分类号： A61K35/17 , A61K38/1774 , A61P35/00 , C07K16/2803 , C07K16/2887 , C07K16/2896 , C12N15/85 , A61K2039/505 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2319/03 , C07K2319/33
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.
-
公开(公告)号：US11542488B2
公开(公告)日：2023-01-03
申请号：US15327778
申请日：2015-07-21
摘要： Sortase molecules and methods described herein allow for the construction of a CAR or CAR member, e.g., in situ, on a CARX, e.g., CART, cell. For example, sortase mediated transfer of an antigen binding domain, e.g., a scFv, onto a CAR member having a sortase acceptor motif in place of an antigen binding domain can provide for a complete CAR member on a cell wherein the cell does not comprise nucleic acid that encodes the complete CAR member.
-
-
-
-
-
-
-
-
-
搜索结果
59 条记录 (耗时 0.069 秒)
